Accord Healthcare – Recall of daptomycin injection

- On December 27, 2022, the FDA announced a consumer level recall of a single lot of Accord Healthcare's daptomycin 500 mg/vial injection and a single lot of daptomycin 350 mg/vial injection due to a complaint report from a hospital pharmacy that vials labeled as "daptomycin for injection 500 mg/vial" were found in cartons labeled as "daptomycin for injection 350 mg/vial".
    - Other daptomycin injection vials that are not being recalled are available.
- This recalled lots were distributed nationwide to wholesalers.

Product Description	NDC#	Lot# (Expiration Date)
Daptomycin for injection 500 mg/vial	16729-435-05	R2200232 (1/2025)
Daptomycin for injection 350 mg/vial	16729-434-05	

- Daptomycin is used for the treatment of adult and pediatric patients with complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of the following Gram-positive bacteria: *Staphylococcus aureaus* (including methicillin-resistant isolates), *Streptococcus pyogenes*, *Streptococcus agalactiae, Streptococcus dysgalactiae subsp. equisimilis*, and *Enterococcus faecalis* (vancomycin-susceptible isolates only).
- The lot and expiration date printed on the outer carton and inner vial are the same and correspond to "daptomycin for injection 500 mg/vial." Accordingly, Accord is voluntarily recalling all of lot R2200232, daptomycin for injection 500 mg/vial, which may be in outer cartons that read "daptomycin for injection 500 mg/vial" or "daptomycin for injection 350 mg/vial."
- To date, Accord has not received any reports of adverse events related to this recall.
- Patients who have the recalled daptomycin should contact their physician or health care provider if they have experienced any problems that may be related to using the recalled product.
- Anyone with an existing inventory of the recalled product should stop use, distribution and quarantine the product immediately.
- For any questions regarding this recall, contact Accord by phone at **1-855-869-1081**, fax: **1-817-868-5362** or e-mail at **rxrecalls@inmar.com**.